CN102423335B - Medicine combination for treating impotence and premature ejaculation and preparation method thereof - Google Patents
Medicine combination for treating impotence and premature ejaculation and preparation method thereof Download PDFInfo
- Publication number
- CN102423335B CN102423335B CN2011103699851A CN201110369985A CN102423335B CN 102423335 B CN102423335 B CN 102423335B CN 2011103699851 A CN2011103699851 A CN 2011103699851A CN 201110369985 A CN201110369985 A CN 201110369985A CN 102423335 B CN102423335 B CN 102423335B
- Authority
- CN
- China
- Prior art keywords
- radix
- stir
- fructus tribuli
- acanthopanacis senticosi
- caulis acanthopanacis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 201000001881 impotence Diseases 0.000 title claims abstract description 27
- 206010036596 premature ejaculation Diseases 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 229940079593 drug Drugs 0.000 title claims description 8
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 241001251068 Formica fusca Species 0.000 claims description 31
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 241000131808 Scolopendra Species 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 12
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 11
- 239000003826 tablet Substances 0.000 claims description 8
- 238000002481 ethanol extraction Methods 0.000 claims description 6
- 238000007796 conventional method Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims 3
- 239000000890 drug combination Substances 0.000 claims 3
- 210000004185 liver Anatomy 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 9
- 210000003734 kidney Anatomy 0.000 abstract description 4
- 230000009986 erectile function Effects 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 2
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 abstract 1
- 241000257303 Hymenoptera Species 0.000 abstract 1
- 244000141009 Hypericum perforatum Species 0.000 abstract 1
- 235000017309 Hypericum perforatum Nutrition 0.000 abstract 1
- 241001165494 Rhodiola Species 0.000 abstract 1
- 241000159213 Zygophyllaceae Species 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 235000009165 saligot Nutrition 0.000 abstract 1
- 238000000638 solvent extraction Methods 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 239000012141 concentrate Substances 0.000 description 12
- 230000001568 sexual effect Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 3
- 229940126678 chinese medicines Drugs 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000003899 penis Anatomy 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000013542 behavioral therapy Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 230000035943 smell Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000005736 Nervous System Malformations Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241001062472 Stokellia anisodon Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicine combination for treating impotence and premature ejaculation and a preparation method thereof. The medicine combination is a preparation prepared by the following main raw materials: fried caltrop, acanthopanax, hypericum perforatum, rhodiola and black ants. The medicine combination disclosed by the invention has the effects of soothing liver and tonifying kidney, and tonifying qi and promoting blood circulation and removing obstruction in channels, and has the advantages that the curative effect is exact, the price is cheap, no side effects are produced, the erectile function of a patient can be quickly improved, the hardness of the erection is increased, the erection duration and the ejaculatory latency are prolonged, the total effective rate is 88%, the total effectual rate is 68%, and the clinical curative rate is 28%. The invention also discloses a preparation method of the medicine combination. In the preparation method, according to the different characteristics of traditional Chinese medicines, the traditional Chinese medicines are preprocessed respectively through grinding or solvent extraction, and other methods, and are then proportioned to be prepared into the product.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of sexual impotence, premature ejaculation.Be the Chinese patent medicine that primary raw material is prepared from stir-baked FRUCTUS TRIBULI, Radix Et Caulis Acanthopanacis Senticosi, Herba Hyperici Monogyni, Radix Rhodiolae, Formica fusca specifically.The invention still further relates to manufacturing method for above mentioned medicine.
Background technology
Sexual impotence claims erection disturbance (being called for short ED in the world) again, refer to that when having libido to require penis anorthosis or erect not hardly erects and to a certain degree hardness is arranged though perhaps have, but the enough time that can not keep sexual intercourse, thereby hinder sexual intercourse maybe can not finish sexual intercourse.Sexual impotence is divided two kinds of congenital and pathologic, and the former is rare, is difficult for curing; The latter sees that clinical treatment has certain curative effect more, and 52% sexual impotence of suffering from was in various degree arranged among the man according to statistics in 40～70 years old.When the definition of premature ejaculation refers to sexual intercourse ejaculate after can not controlling the sufficiently long time in the bridegroom's or husband's side, causes in the normal women's at least 50% of sexual function the normal sexual intercourse to be not being met.Sexual impotence and premature ejaculation often happen in company with clinically.Therapeutic Method has behavior therapy, operation and Drug therapy.Behavior therapy generally adopts sexy training and " squeezing " therapy concentrated, uncertain therapeutic efficacy cut and onset slow; Operative treatment has certain risk, and in the art, postoperative can leave over complication, the patient is difficult for accepting; Drug therapy has viagra, Ai Lida, Xi Aili etc., mostly is the import medicine, and is expensive, and side effect such as headache, Blushing, dyspepsia, visual disorder, cardiovascular accident are arranged.
Though research at present has the Chinese patent medicine of some treatment sexual impotence, premature ejaculation, but still can not satisfy patient's needs, and its prescription composition is all complicated, flavour of a drug are more, and price is higher, unsatisfactory curative effect.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine and corresponding preparations thereof for the treatment of sexual impotence, premature ejaculation determined curative effect.Its characteristics have: can comparatively fast improve patient's erection function, the hardness of increase erecing, prolong erect persistent period and ejaculation latency, and low price, have no side effect.
The traditional Chinese medical science is thought sexual impotence, premature ejaculation pathogeny and stagnation of liver-QI blood stasis, the smart not intrinsic pass of closing of suffering from a deficiency of the kidney.Liver governing tendons, external genitals are the remittance of penis, if feelings will is unsuccessful, and anxiety and rage, the liver failing to maintain the normal flow of QI bar reaches, obstruction of collaterals by blood stasis, and then penis gathers incapability, says as " cloudy source and course behind the miscellaneous diseases source and course rhinoceros candle external genitalia ": " people that mental confusion is arranged; depressed impairing the liver, edema with the liver involved can not be dredged and be reached, and also causes impotence and does not rise "; Again because of excess of sexual intercourse, or the juvenile masturbation of frequently violating, or marriage and childbirth too early, or fear impairing kidney, so that vital essence is deficient, causes impotence.
Solution of the present invention is based on motherland's medical science to the understanding of the basic pathogenesis of sexual impotence, premature ejaculation, according to oneself clinical experience for many years, from numerous Chinese medicines, determine a series for the treatment of sexual impotence, the effective Chinese medicine of premature ejaculation earlier, again through clinical checking repeatedly, the compound Chinese medicinal preparation that screens.Effect with soothing the liver the kidney invigorating, benefiting QI for activating blood circulation collateral dredging can comparatively fast be improved patient's erection function, the hardness that increase is erected, and prolongs erect persistent period and ejaculation latency.
The present invention is a kind of pharmaceutical composition for the treatment of sexual impotence, premature ejaculation, it is characterized in that it is is that primary raw material is prepared from stir-baked FRUCTUS TRIBULI, Radix Et Caulis Acanthopanacis Senticosi, Herba Hyperici Monogyni, Radix Rhodiolae, Formica fusca.
Weight proportion is composed as follows:
(1) stir-baked FRUCTUS TRIBULI 10-50 part, Radix Et Caulis Acanthopanacis Senticosi 10-50 part, Herba Hyperici Monogyni 5-30 part, Radix Rhodiolae 10-40 part, Formica fusca 10-40 part.
The preferred weight proportioning is:
(2) stir-baked FRUCTUS TRIBULI 20-40 part, Radix Et Caulis Acanthopanacis Senticosi 20-40 part, Herba Hyperici Monogyni 5-20 part, Radix Rhodiolae 10-30 part, Formica fusca 10-30 part.
Medicine composition of the present invention can also contain one or more in the Chinese medicines such as the Radix Paeoniae Alba, Scolopendra, Herba Epimedii.
Medicine of the present invention can be the medicine of said dosage form on any pharmaceutics.
The preparation of this medicine can prepare by the conventional method on the various medicaments, as:
Scolopendra is ground into fine powder, or uses ethanol extraction; Stir-baked FRUCTUS TRIBULI, Radix Et Caulis Acanthopanacis Senticosi, Herba Hyperici Monogyni, Radix Rhodiolae, Formica fusca, the Radix Paeoniae Alba, Herba Epimedii are extracted according to a conventional method with ethanol or water etc., concentrate, drying gets extract, makes the medicine of required dosage form.
In the above preparation process, if necessary, can add adjuvant commonly used in an amount of pharmaceutics, as starch, dextrin, microcrystalline cellulose, amylum pregelatinisatum, magnesium stearate, micropowder silica gel, sucrose, carboxymethyl starch sodium etc.
For verifying that further the present invention treats the effect of sexual impotence, premature ejaculation, has carried out following pharmacodynamics test.
The influence of 1 pair of castration mouse sexual function
Select healthy Male Kunming strain mice for use, body weight 18～20g, except normal blank group (N group), all the other animals are excised bilateral testes under the ether light anaesthesia, and the postoperative local wound is dripped with gentamycin sulfate.Behind the operation 3d, animal is divided into castration model group (M group), of the present invention group (F group), soothing the liver Yiyang Capsules group (S group), Fructus Tribuli extract group (J group), 10 every group at random.Each treated animal gastric infusion every day 1 time, N group and M group only wait the capacity distilled water to irritate stomach, continuous 28d.Other gets female mice with condition cage raising in addition.
After the administration of animal last, 1 male Mus is put into transparent observing case 10min, can enough shake down, every case adds 1 with batch female mice of raising then.Record following index: 1. be fed into male Mus from female Mus and pounce on the time (pounce on and catch incubation period) of catching female Mus for the first time; 2. be fed into male Mus ejaculate the time for the first time (ejaculation latency) from female Mus; 3. male Mus pounces on and catches number of times in the 20min; 4. each treated animal is pounced on the number of animals of catching, ejaculating in the 20min, pounces on the rate of catching (%) and ejaculation rate (%).The results are shown in Table 1.
Table 1 respectively organize mice pounce on catch, ejaculation latency (s) and number of times relatively
Annotate:
*Compare with the M group, P＜0.05,
*Compare P＜0.01 with the M group;
△Compare with the F group, P＜0.05, down together
By table 1 as seen, compare with the N group, M group mice pounces on to catch and obviously prolongs incubation period, and ejaculation latency shortens, and pounces on and catches number of times minimizing (P＜0.05 and P＜0.01); Male Mus mating ability obviously strengthens after giving of the present invention group of (F group) 28d, show as to pounce on after mating and catch female Mus and obviously shorten incubation period, the number of times increase is caught in pouncing on of finishing in the 20min, ejaculation latency obviously prolongs simultaneously, full treated animal is pounced on the rate of catching, mating rate increases, of the present invention group (F group) obviously is better than soothing the liver Yiyang Capsules group (S group) and Fructus Tribuli extract group (J group), illustrates that of the present invention group can strengthen erection and sexual potency, improves ejaculation functions such as premature ejaculation.
The experimentation of 2 pairs of depression of liver-QI rat model sexual activity influences
2.1 laboratory animal
50 of the male adult rats of Wistar, body constitution amount 200～240g provides (No. 8, the real moving Guan Zhidi in river) by Chengdu University of Traditional Chinese Medicine's Experimental Animal Center.
2.2 experimental technique
2.2.1 the animal grouping is divided into 5 groups at random with rat: blank group (N group), model group (M group), of the present invention group (F group), Fructus Tribuli extract group (J group) and soothing the liver Yiyang Capsules group (S group), 10 every group.
2.2.2 modelling and administration are with reference to the unsettled pedal hanging reduction that repeats of reports such as Lian Xiaoyuan, every day 1 time, continuous 10d, and increase the suspention time in proper order, to cause liver qi stagnation type sexual dysfunction model, press the 10ml/Kg gastric infusion, 1 time/d, N group and M group only wait the capacity distilled water to irritate stomach, successive administration 28d.
2.2.3 behind the last administration 12h of the observation of rat sexual activity, in the darkroom, get a male Mus and put into observation cage 10min, it is conformed, drop into 2 female Mus of estrogenization then, shooting is synchronously observed male Mus and is smelt the perineum of licking female Mus, the number of times of mouth, catches the number of times that the interior male Mus of incubation period, ejaculation latency and 20min catches female Mus.
2.3 result: each is organized the rat sexual activity and relatively sees Table 2.
Table 2 is respectively organized rat sexual activity situation
By table 2 as seen, compare with the N group, M group rat smells and licks number of times, catches number of times minimizing (P＜0.05 and P＜0.01), catches obviously to prolong (P＜0.01) incubation period, and ejaculation latency shortens (P＜0.05); Male Mus sexuality obviously strengthens after giving of the present invention group of 28d, show as to pounce on to catch and smell and lick number of times and increase, catch and shorten incubation period, ejaculation latency obviously prolongs simultaneously, of the present invention group obviously is better than soothing the liver Yiyang Capsules group (S group) and Fructus Tribuli extract group (J group), illustrate that the liver qi stagnation type impotence model that this experiment copies is successful, of the present invention group can strengthen the erection of depression of liver-QI rat model and sexual potency, improve ejaculation functions such as premature ejaculation.
For further showing clinical effectiveness of the present invention, with reference to " the clinical research guideline of new Chinese medicine treatment sexual impotence, premature ejaculation ", select 20～60 years old, be diagnosed as patient's 50 examples of sexual impotence, premature ejaculation, through the objective clinical observation of system.Minimum 25 years old of age, maximum 59 years old, average 46.77 ± 12.05 years old.The course of disease is the shortest 7 months, and is the longest 36 months, average 23.19 ± 5.22 months.9 examples that the state of an illness is slight (18%), moderate 26 examples (52%), severe 15 examples (30%).One month observation period.Respectively at taking medicine preceding and taking medicine the back observation:
(1) safety indexes: blood pressure, pulse, blood, urine, stool three big routines and electrocardiogram, liver, kidney function test.
(2) health giving quality index:
1. IIEF-5 scoring.
2. tcm syndrome scoring.
(3) untoward reaction is observed
Comprise gastrointestinal reaction, nervous system abnormality, skin abnormality etc.
Every index changes shown in table 3～5 before and after the treatment
(IIEF-5) variation of marking of table 3 international index of erectile function (questionnaire)
Notes: * * represents and preceding relatively p＜0.01 for the treatment of (down together).
The scoring of table 4 tcm syndrome changes
Annotate: the p value representation is the same.
The evaluation of table 5 total effects
Do not see obvious adverse reaction in the drug administration process, electrocardiogram before and after taking medicine, liver, renal function, blood, urine, stool routine examination do not have significant change.
Clinical drug of the present invention uses the result to show that following advantage is arranged:
(1) obviously improve the tcm symptom of sexual impotence, premature ejaculation, and not hard, feelings will is not smooth as sexual impotence erectile problem or act, and ambition is gloomy, fullness and distention in the chest and hypochondrium, soreness of the waist and knees, premature ejacuation emission, insomnia and dreamful sleeps etc. increase international index of erectile function (questionnaire) and (IIEF-5) mark, and improve the quality of living;
(2) obviously increase patient's erection hardness;
(3) obviously prolong the erection persistent period;
(4) obviously prolong ejaculation latency;
(5) have no side effect.
The specific embodiment
The invention will be further described below in conjunction with embodiment.
The present invention is composed as follows by weight ratio:
(1) stir-baked FRUCTUS TRIBULI 10-50 part, Radix Et Caulis Acanthopanacis Senticosi 10-50 part, Herba Hyperici Monogyni 5-30 part, Radix Rhodiolae 10-40 part, Formica fusca 10-40 part.
Preferred weight proportioning of the present invention is:
(2) stir-baked FRUCTUS TRIBULI 20-40 part, Radix Et Caulis Acanthopanacis Senticosi 20-40 part, Herba Hyperici Monogyni 5-20 part, Radix Rhodiolae 10-30 part, Formica fusca 10-30 part.
Medicine composition of the present invention can also contain one or more in the Chinese medicines such as the Radix Paeoniae Alba, Scolopendra, Herba Epimedii, and proportioning is composed as follows:
(3) stir-baked FRUCTUS TRIBULI 20-40 part, Radix Et Caulis Acanthopanacis Senticosi 20-40 part, Herba Epimedii 10-40 part, Herba Hyperici Monogyni 5-20 part, Radix Rhodiolae 10-30 part, Formica fusca 10-30 part.
(4) stir-baked FRUCTUS TRIBULI 20-40 part, Radix Et Caulis Acanthopanacis Senticosi 20-40 part, Radix Paeoniae Alba 10-30 part, Herba Hyperici Monogyni 5-20 part, Radix Rhodiolae 10-30 part, Formica fusca 10-30 part.
(5) stir-baked FRUCTUS TRIBULI 20-40 part, Radix Et Caulis Acanthopanacis Senticosi 20-40 part, Herba Hyperici Monogyni 5-20 part, Radix Rhodiolae 10-30 part, Formica fusca 10-30 part, Scolopendra 0.5-10 part.
(6) stir-baked FRUCTUS TRIBULI 20-40 part, Radix Et Caulis Acanthopanacis Senticosi 20-40 part, Herba Epimedii 10-40 part, Herba Hyperici Monogyni 5-20 part, Radix Rhodiolae 10-30 part, Formica fusca 10-30 part, Scolopendra 0.5-10 part.
(7) stir-baked FRUCTUS TRIBULI 20-40 part, Radix Et Caulis Acanthopanacis Senticosi 20-40 part, Radix Paeoniae Alba 10-30 part, Herba Hyperici Monogyni 5-20 part, Radix Rhodiolae 10-30 part, Formica fusca 10-30 part, Scolopendra 0.5-10 part.
1, the preparation method of medicine of the present invention is example with stir-baked FRUCTUS TRIBULI 20-40 part, Radix Et Caulis Acanthopanacis Senticosi 20-40 part, Herba Hyperici Monogyni 5-20 part, Radix Rhodiolae 10-30 part, Formica fusca 10-30 part, can be with reference to following method:
(1) the Radix Et Caulis Acanthopanacis Senticosi water is pressed decocting method and extracted, concentrate, get water extract; With stir-baked FRUCTUS TRIBULI, Herba Hyperici Monogyni, Formica fusca, Radix Rhodiolae ethanol extraction, reclaim solvent, concentrate, get alcohol extract, with water extract mixing, drying, granulate, be processed into tablet, capsule or granule.
(2) stir-baked FRUCTUS TRIBULI, Radix Et Caulis Acanthopanacis Senticosi, Herba Hyperici Monogyni, Radix Rhodiolae, Formica fusca water are pressed decocting method and extracted, concentrate, drying is granulated, and is processed into tablet, capsule or granule.
2, the preparation method of medicine of the present invention, the preparation that consists of stir-baked FRUCTUS TRIBULI 20-40 part, Radix Et Caulis Acanthopanacis Senticosi 20-40 part, Herba Epimedii 10-40 part, Herba Hyperici Monogyni 5-20 part, Radix Rhodiolae 10-30 part, Formica fusca 10-30 part, can be with reference to following method:
(1) Radix Et Caulis Acanthopanacis Senticosi, Herba Epimedii water are pressed decocting method and extracted, concentrate, get water extract; With stir-baked FRUCTUS TRIBULI, Herba Hyperici Monogyni, Formica fusca, Radix Rhodiolae ethanol extraction, reclaim solvent, concentrate, get alcohol extract, with water extract mixing, drying, granulate, be processed into tablet, capsule or granule.
(2) stir-baked FRUCTUS TRIBULI, Radix Et Caulis Acanthopanacis Senticosi, Herba Epimedii, Herba Hyperici Monogyni, Radix Rhodiolae, Formica fusca water are pressed decocting method and extracted, concentrate, drying is granulated, and is processed into tablet, capsule or granule.
3, the preparation method of medicine of the present invention, the preparation that consists of stir-baked FRUCTUS TRIBULI 20-40 part, Radix Et Caulis Acanthopanacis Senticosi 20-40 part, Radix Paeoniae Alba 10-30 part, Herba Hyperici Monogyni 5-20 part, Radix Rhodiolae 10-30 part, Formica fusca 10-30 part, Scolopendra 0.5-10 part, can be with reference to following method:
(1) Radix Et Caulis Acanthopanacis Senticosi, Radix Paeoniae Alba water are pressed decocting method and extracted, concentrate, get water extract; With stir-baked FRUCTUS TRIBULI, Herba Hyperici Monogyni, Formica fusca, Radix Rhodiolae, Scolopendra ethanol extraction, reclaim solvent, concentrate, get alcohol extract, with water extract mixing, drying, granulate, be processed into tablet, capsule or granule.
(2) Scolopendra is ground into fine powder; Radix Et Caulis Acanthopanacis Senticosi, Radix Paeoniae Alba water are pressed decocting method extract, concentrate, get extract; With stir-baked FRUCTUS TRIBULI, Herba Hyperici Monogyni, Formica fusca, Radix Rhodiolae ethanol extraction, reclaim solvent, concentrate, get alcohol extract, with water extract, Scolopendra fine powder mix homogeneously, drying, granulate, be processed into tablet, capsule or granule.
(3) Scolopendra is ground into fine powder; Stir-baked FRUCTUS TRIBULI, Radix Et Caulis Acanthopanacis Senticosi, the Radix Paeoniae Alba, Herba Hyperici Monogyni, Radix Rhodiolae, Formica fusca water are pressed decocting method extract, concentrate, drying is granulated, and is processed into tablet, capsule or granule.
Claims (10)
1. a pharmaceutical composition for the treatment of sexual impotence, premature ejaculation is characterized in that it is to be made by following raw materials by weight proportions: stir-baked FRUCTUS TRIBULI 10-50 part, Radix Et Caulis Acanthopanacis Senticosi 10-50 part, Herba Hyperici Monogyni 5-30 part, Radix Rhodiolae 10-40 part, Formica fusca 10-40 part.
2. pharmaceutical composition according to claim 1 is characterized in that each drug weight ratio range is in the crude drug: stir-baked FRUCTUS TRIBULI 20-40 part, Radix Et Caulis Acanthopanacis Senticosi 20-40 part, Herba Hyperici Monogyni 5-20 part, Radix Rhodiolae 10-30 part, Formica fusca 10-30 part.
3. a pharmaceutical composition for the treatment of sexual impotence, premature ejaculation is characterized in that it is to be made by following raw materials by weight proportions: stir-baked FRUCTUS TRIBULI 20-40 part, Radix Et Caulis Acanthopanacis Senticosi 20-40 part, Herba Epimedii 10-40 part, Herba Hyperici Monogyni 5-20 part, Radix Rhodiolae 10-30 part, Formica fusca 10-30 part.
4. a pharmaceutical composition for the treatment of sexual impotence, premature ejaculation is characterized in that it is to be made by following raw materials by weight proportions: stir-baked FRUCTUS TRIBULI 20-40 part, Radix Et Caulis Acanthopanacis Senticosi 20-40 part, Herba Hyperici Monogyni 5-20 part, Radix Rhodiolae 10-30 part, Formica fusca 10-30 part, Scolopendra 0.5-10 part.
5. a pharmaceutical composition for the treatment of sexual impotence, premature ejaculation is characterized in that it is to be made by following raw materials by weight proportions: stir-baked FRUCTUS TRIBULI 20-40 part, Radix Et Caulis Acanthopanacis Senticosi 20-40 part, Herba Epimedii 10-40 part, Herba Hyperici Monogyni 5-20 part, Radix Rhodiolae 10-30 part, Formica fusca 10-30 part, Scolopendra 0.5-10 part.
6. a pharmaceutical composition for the treatment of sexual impotence, premature ejaculation is characterized in that it is to be made by following raw materials by weight proportions: stir-baked FRUCTUS TRIBULI 20-40 part, Radix Et Caulis Acanthopanacis Senticosi 20-40 part, Radix Paeoniae Alba 10-30 part, Herba Hyperici Monogyni 5-20 part, Radix Rhodiolae 10-30 part, Formica fusca 10-30 part, Scolopendra 0.5-10 part.
7. according to each described pharmaceutical composition in the claim 1 to 6, it is characterized in that the dosage form of said pharmaceutical composition is selected from granule or tablet or capsule.
8. prepare each described preparation of drug combination method in the claim 1 to 2, it is characterized in that: stir-baked FRUCTUS TRIBULI, Radix Et Caulis Acanthopanacis Senticosi, Herba Hyperici Monogyni, Radix Rhodiolae, Formica fusca water or alcoholic solution are extracted according to a conventional method, then each extract is mixed evenly, make required forms of pharmaceutical compositions.
9. prepare preparation of drug combination method described in the claim 3, it is characterized in that: stir-baked FRUCTUS TRIBULI, Radix Et Caulis Acanthopanacis Senticosi, Herba Epimedii, Herba Hyperici Monogyni, Radix Rhodiolae, Formica fusca water or alcoholic solution are extracted according to a conventional method, then each extract is mixed evenly, make required forms of pharmaceutical compositions.
10. preparation of drug combination method described in the preparation claim 6 is characterized in that: with the Scolopendra ethanol extraction, reclaim solvent, get extract; Stir-baked FRUCTUS TRIBULI, Radix Et Caulis Acanthopanacis Senticosi, the Radix Paeoniae Alba, Herba Hyperici Monogyni, Radix Rhodiolae, Formica fusca water or alcoholic solution are extracted according to a conventional method, then each extract is mixed evenly, make required forms of pharmaceutical compositions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103699851A CN102423335B (en) | 2011-11-21 | 2011-11-21 | Medicine combination for treating impotence and premature ejaculation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103699851A CN102423335B (en) | 2011-11-21 | 2011-11-21 | Medicine combination for treating impotence and premature ejaculation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102423335A CN102423335A (en) | 2012-04-25 |
| CN102423335B true CN102423335B (en) | 2013-08-28 |
Family
ID=45957422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103699851A Active CN102423335B (en) | 2011-11-21 | 2011-11-21 | Medicine combination for treating impotence and premature ejaculation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102423335B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102872206B (en) * | 2012-10-12 | 2014-10-29 | 中国医学科学院药用植物研究所云南分所 | Traditional Chinese medicine compound capable of improving immunity, resisting fatigue and improving sexual function |
| CN102988505B (en) * | 2012-12-24 | 2014-02-26 | 郭凯 | Medicine composition for treating erectile dysfunction and preparation method thereof |
| CN103087889A (en) * | 2012-12-28 | 2013-05-08 | 广西东兴市创新特色医药科技发展有限公司 | Aphrodisiac wine and preparation method thereof |
| EP3142668B1 (en) * | 2014-05-15 | 2020-06-03 | IDI Integratori Dietetici Italiani S.r.l. | A formulation for ameliorating premature ejaculation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101530531A (en) * | 2008-03-14 | 2009-09-16 | 何家宁 | Panwang vigor pill for improving the functions of human body and preparation method thereof |
-
2011
- 2011-11-21 CN CN2011103699851A patent/CN102423335B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101530531A (en) * | 2008-03-14 | 2009-09-16 | 何家宁 | Panwang vigor pill for improving the functions of human body and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 从肝郁论治中青年阳痿;王勇;《北京中医》;20060228;第25卷(第2期);86，87 * |
| 抗抑郁症的中药及维吾尔医药研究进展;阿不力皮孜;《新疆医科大学学报》;20111031;第34卷(第10期);1134－1137 * |
| 王勇.从肝郁论治中青年阳痿.《北京中医》.2006,第25卷(第2期),86,87. * |
| 阿不力皮孜.抗抑郁症的中药及维吾尔医药研究进展.《新疆医科大学学报》.2011,第34卷(第10期),1134－1137. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102423335A (en) | 2012-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102764339B (en) | Maca composition for improving sexual dysfunction and preparation method and application thereof | |
| CN103830632A (en) | Chinese traditional medicine preparation for radically treating psoriasis and multiple skin diseases and preparation method and application thereof | |
| CN102423335B (en) | Medicine combination for treating impotence and premature ejaculation and preparation method thereof | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN103520646B (en) | Chinese medicine composition for treating depression and preparation method of Chinese medicine composition | |
| CN104147180B (en) | Pharmaceutical composition for the treatment of immunologic thrombocytopenic purpura and preparation method thereof | |
| CN105943651A (en) | Traditional Chinese medicine composition for treating premature ovarian failure, and application thereof | |
| CN102641478B (en) | Oral medicament for treating hyperplasia of mammary glands | |
| CN102579849B (en) | Sodium valproate and preparation process thereof | |
| CN104523603A (en) | Traditional Chinese medicine granules and preparation method and use thereof | |
| CN103191399A (en) | Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period | |
| CN101642502B (en) | Male moth yang-strengthening compound preparation formula and preparation technique thereof | |
| CN107412661A (en) | A kind of Chinese medicine composition for treating impotence, premature ejaculation and preparation method thereof | |
| CN103585449A (en) | Traditional Chinese medicine composition for treating migraine | |
| CN1907335A (en) | Pharmaceutical composition for treating nasosinusitis and its preparing process | |
| CN102988892A (en) | Medicament for treating hysteromyoma and ovarian cysts | |
| CN102895519B (en) | Chinese medicine for treating allergic rhinitis and preparation method thereof | |
| CN101590126A (en) | A kind of Chinese medicine compound for the treatment of benign prostatic hyperplasia | |
| CN1686514A (en) | Chinese medicinal preparation for treating anxietas, depression and its production method | |
| CN102988505B (en) | Medicine composition for treating erectile dysfunction and preparation method thereof | |
| CN103705857B (en) | For preventing the Chinese medicine composition of oral cavity radiomucitis | |
| CN102631429A (en) | Medicinal composition for treating rheumatoid arthritis and preparation method thereof | |
| CN103251751B (en) | Traditional Chinese medicine composition for treating primary dysmenorrheal and preparation method thereof | |
| CN103705840A (en) | Medicinal composition for treating acute and chronic cholecystitis, and cholelithiasis, and preparation method thereof | |
| CN103142928A (en) | Iliacus muscle oral liquid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 610041 Chengdu City, Sichuan province high tech Zone, Century City Road, Longhu century Feng Jing, building 1, unit 3703, 7 Patentee after: Guo Kai Address before: 610045 Sichuan city of Chengdu province Wuhou District Wu Xing Road No. two building 8, unit 6, notting hill 10 floor, No. 1002 Patentee before: Guo Kai |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20181218 Address after: 610045 1 building, nine Hing Avenue, Chengdu high tech Zone, Chengdu, Sichuan, China. 10 Patentee after: Chengdu front road Biotechnology Co., Ltd. Address before: 610041 Sichuan city Chengdu high tech Zone Century City Road Longhu century peak 7 buildings 1 units 3703 Patentee before: Guo Kai |
|
| TR01 | Transfer of patent right |